Quiet for some time, “a idea of flow,” is back with the try to commence another heat wave. A “state buying and storage orders for 4 million,” the news, yesterday’s resumption of Hualan material strength everyday limit, whilst driving the bio- Pharmacy Plate holding red flag. Nowadays morning, Hualan items nonetheless every day limit of opening, a flow concept stock gainers. Market place phenomena
Collective Medicine Stocks, “laughed colored”
Yesterday, biopharmaceuticals segment is undoubtedly the most beautiful cities and a landscape. Hualan items just a resumption of trading yesterday they rushed daily limit, the other “a flow concept stocks”?? Tat gene, Rhine biology, Neptunus Bioengineering, also followed suit.
Biopharmaceutical whole plate is an “red flags were fluttering” of the scene. Fortune Securities Trading System shows that yesterday 117 biopharmaceutical stocks fell only five.
Morning market place to open reduce nowadays, bio-pharmaceutical stocks mixed in plate, most individual stock value correction, but Hualan point, the Temple of Heaven biology, bio-Rhine, Neptunus Bioengineering, Tat gene, Kehua biological idea of a flow unit trend is nonetheless sturdy.
Industry analysis that appears to the biopharmaceutical plate some unexpected gains from the news side of the actual edge of a “fuse.” Recently, Hualan material received MIIT issued four million a flu vaccine getting and storage orders, and these vaccines are scheduled Sept. 15 to comprehensive the perform of certified test delivery.
It is this news, Hualan consecutive day-to-day limit of things, but also makes the “notion of a stream,” return to the rivers and lakes.
Hot money enthusiastically participated in the “concept of a stream”
“A idea of flow” of funds by the industry when once more concern. Information show that the pharmaceutical industry a net inflow of 974 million yuan yesterday, ranking very first in the market, a net inflow of funds.
It is understood that in this wave of market, the inflow of Chinese funds plate mainly hot funds.
Transaction information, yesterday, Guoxin Securities, a securities organization department of Hangzhou Branch of China net inflow of biological ten.5533 million yuan Guotai Junan Securities, a sales workplace in Chengdu yesterday, is to devote huge to buy Section 37.1312 million yuan of China biological, Neptunus Bioengineering two ” A current concept stock. “
Biopharmaceutical stocks rose this morning, TOP10 (9 opening information) the stock ticker abbreviation opening opening value rise
002007 9.99% 49.53 yuan Hualan house
600161 six.54% 28.00 yuan Tiantan Biological
002166 3.03% 45.60 yuan biological Rhine
000078 two.9% 11.00 yuan Sea King bio
002030 2.84% 16.29 yuan Tat gene
002022 Kehua 2.28% 19.30 yuan biological
000790 2.16% eight.50 yuan Huashenjituan Too long
600222 1.92% 7.95 yuan Medicine
600530 1.71% 9.50 yuan Chiao Tung University Onlly
600572 1.67% 12.20 yuan Kangen Bei
Industry analysts Largest listed firms to advantage from a vaccine production qualification
A flu vaccine production of biological pharmaceuticals in the end plates have significantly impact?
Ministry of Well being had proposed, in the National Day, 13 million will be completed by the reserve size. Investment adviser in the pharmaceutical market researchers estimated that a flu vaccine in accordance with the value no higher than regular purchasing and storage Influenza Vaccine requirements to 25 per 1 rates, a flu vaccine market place worth of at least more than 300 million yuan.
In addition, the marketplace expects the central and regional government acquiring and storage just before the finish of 6500 million doses of a flu vaccine. This also implies that a flu vaccine market worth will be greater.
CSC Securities analyst Liu Yang pointed out the morning with a flu vaccine production is undoubtedly qualified listed companies among the largest beneficiaries.
Changjiang Securities analysts pointed out that a flu vaccine buying and storage price tag but to establish, in accordance with the per dose cost of 20 yuan -30 element calculations, the relevant corporate earnings is really considerable, but the pricing can only be measured against clear efficiency prior to effect.